The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...
In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial ...
In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid ...